DOCSLIB.ORG

Respondents' Reply to Complaint

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Respondents' Reply to Complaint 02 07 2012 UNITED STATES OF AMERICA FEDERAL TRADE COMMISSION In the Matter of ) ) POM WONDERFUL LLC and ) ROLL GLOBAL, as successor in interest ) to Roll International companies, and ) Docket No. 9344 ) P UBLIC ) STEWART A. RESNICK, ) LYNDA RAE RESNICK, and ) MATTHEW TUPPER, individually and ) as officers of the companies. ) ) RESPONDENTS’ REPLY TO COMPLAINT COUNSEL’S POST-TRIAL BRIEF Kristina M. Diaz, Esq. Alicia Mew, Esq. Johnny Traboulsi, Esq. Brooke Hammond, Esq. Roll Law Group P.C. 11444 West Olympic Blvd., 10th Floor Los Angeles, CA, 90064 Tel: 310.966.8400 Fax: 310.966.8810 Email: [email protected] John Graubert, Esq. Bertram Fields, Esq. Skye Perryman, Esq. Greenberg Glusker Fields Covington & Burling LLP Claman & Machtinger, LLP 1201 Pennsylvania Avenue, NW 1900 Avenue of the Stars, Suite 2100 Washington, DC 20004 Los Angeles, CA 90067 Tel: 202.662.6000 Tel: 310.553.3610 Fax: 202.662.6291 Fax: 310.553.0687 Email: [email protected] Email: [email protected] {060188.3} RECORD REFERENCES References to the record are made using the following citation forms and abbreviations: Appendix of Advertisements – Respondents’ Appendix of Advertisements (submitted with initial Post Trial Brief) Reply Ad Appendix – Respondents’ Reply Appendix of Advertisements CX – Complaint Counsel exhibit PX – Respondents exhibit RPTB – Respondents’ Post Trial Brief RFF – Respondents’ Proposed Findings of Fact RCL – Respondents’ Proposed Conclusions of Law RRFF – Respondents’ Reply Findings of Fact CCPTB – Complaint Counsel’s Post Trial Brief RRCL – Respondents’ Reply Conclusions of Law Tr. – Trial testimony (CX0000 at 000 (XX, Dep. at xx)) – Citations to deposition testimony from this litigation (CX0000 at 000 (XX, Dep. at xx), in camera) – Citations to in camera deposition testimony from this litigation (CX0000 at 000 (XX, OS Dep. at xx)) – Citations to Deposition Testimony from POM Wonderful LLC v. Ocean Spray Cranberries, Inc., No. CV-09-00565 DDP (RZx) (C.D. Cal.) (CX0000 at 000 (XX, TCCC Dep. at xx)) – Citations to Deposition Testimony from POM Wonderful LLC v. The Coca-Cola Co., No. CV-08-06237 SJO (FMOx) (C.D. Cal.) (CX0000 at 000 (XX, Trop. Dep. at xx)) – Citations to Deposition Testimony from POM Wonderful LLC v. Tropicana Prods., Inc., No. CV-09-00566 DSF (CTx) (C.D. Cal.) (CX0000 at 000 (XX, Welch Dep. at xx)) – Citations to Deposition Testimony from POM Wonderful LLC v. Welch Foods, Inc., No. CV-09-00567 AHM (AGRx) (C.D. Cal.) Joint Stipulations of Law and Fact, JX0001 (or JX0003) ¶ - Citation to Joint Stipulations of Fact and Law CCFF – Complaint Counsel’s Proposed Findings of Fact CCCL – Complaint Counsel’s Proposed Conclusions of Law {060188.3} TABLE OF CONTENTS I. INTRODUCTION AND STATEMENT OF FACTS ........................................................ 1 II. POM’S ADVERTISING IS NOT DECEPTIVE AND DOES NOT VIOLATE SECTIONS 5 AND 12 OF THE FTCA .............................................................................. 5 A. Complaint Counsel’s Facial Analysis of the Challenged Ads Is Defective and Fails to Demonstrate that the Challenged Ads Convey the Establishment and Efficacy Claims Complaint Counsel Assign to Them .............. 5 1. The Challenged Establishment Advertisements, Viewed as a Whole, Do Not Clearly and Conspicuously Convey the Broad “Clinically Proven” Claims Complaint Counsel Seeks to Attach to Them ........................................................................................................... 8 2. The Challenged Efficacy Advertisements, Viewed as a Whole, Do Not Clearly and Conspicuously Convey Efficacy Disease Claims to a Reasonable Consumer........................................................................ 29 B. Complaint Counsel Failed to Present Any Reliable Extrinsic Evidence to Establish the Claims They Attribute to the Challenged Advertisements .............. 34 C. Respondents Did Not Intend to Convey Establishment and Efficacy Claims That the Challenged Products Treat, Prevent or Reduce the Risk of Heart Disease, Prostate Cancer, and Erectile Dysfunction ................................... 43 1. Inclusion of Studies and Health Claims in POM’s Ads Does Not Show Respondents Intended to Convey the Claims That the Products Treat, Prevent or Reduce the Risk of Disease ............................ 43 2. Citation to Money Spent on Research in POM’s Ads Does Not Show Respondents Intended to Convey the Claims That the Products Treat, Prevent or Reduce the Risk of Disease ............................ 48 3. POM’s Focus on Health Conscious Buyers Does Not Prove Respondents Intended to Convey the Claims that the Products Treat, Prevent or Reduce the Risk of Disease........................................... 48 a. The Medium in Which POM Advertised Does Not Show Respondents’ Intent to Convey the Challenged Claims ............... 49 b. POM’s Creative Briefs Are Irrelevant to Show Respondents’ Intent to Convey the Challenged Claims ............... 51 D. The Challenged Claims Are Not Material To Consumers’ Decisions to Purchase POM Juice ............................................................................................. 53 1. Respondents Rebutted Any Initial Presumption of Materiality Because the Reibstein Survey Unequivocally Demonstrates that the Challenged Claims Are Not Material Because Consumers Purchase POM Juice For Non-Disease Related Reasons ......................... 55 {060188.3} i 2. The Non-Expert Consumer Research Relied Upon By Complaint Counsel Do Not Show That the Challenged Claims Are Material ........... 59 a. The A&U Study is Methodologically Flawed and Sheds No Light on the Materiality of the Challenged Claims ...................... 59 b. The Zoomerang Survey is Methodologically Flawed and Sheds No Light on the Materiality of the Challenged Claims ........................................................................................... 63 3. Dr. Reibstein Never Testified That the Challenged Claims Would Motivate Consumers to Buy the Challenged Products ............................. 64 4. Materiality of the Challenged Claims Cannot be Inferred From the Notices Respondents Received about Their Science and Advertising................................................................................................ 65 E. Respondents’ Claims Do Not Constitute Broad “Treat,” “Prevent,” or “Reduce the Risk” Establishment Claims That Excuse Complaint Counsel From Meeting Their Burden Under Pfizer And Evaluating POM’s Significant Body Of Research .............................................................................. 69 1. The Proper Standard to Review Respondents’ Claims Is Under Pfizer ......................................................................................................... 73 2. Complaint Counsel’s Proposition That Only RCTs are Sufficient to Substantiate Health Claims Is Baseless Both Legally and Scientifically ............................................................................................. 74 a. There Is No Legal Requirement of RCTs to Substantiate a Safe Whole Food Product and “RCTs” Are Not Required to Show a Causal Relationship Between a Health Benefit and Product. ......................................................................................... 76 b. There Is No Scientific Basis Requiring RCTs to Substantiate a Safe Whole Food Product. ..................................... 82 c. The Challenged Products Are Safe 100% Whole Food Products That Are Not Offered In Place of Conventional Medical Treatment ........................................................................ 88 F. POM’s Heart Health Claims Are True and Substantiated by Competent and Reliable Scientific Evidence .......................................................................... 90 1. The Appropriate Evidentiary and Scientific Standard for Evaluating the Effect of a Fruit or Fruit Juice, Such As Pomegranate Juice (and Its Derivatives), on Cardiovascular Health Is Not RCTs .............................................................................................. 90 2. Respondents Possess Competent and Reliable Evidence to Substantiate the Health Benefit Claims Made Regarding the Challenged Products ................................................................................. 93 ii a. Respondents’ Scientific Research Demonstrates a Benefit in Lowering Blood Pressure.......................................................... 93 b. Respondents’ Scientific Research Demonstrates a Benefit in Reducing Arterial Plaque.......................................................... 94 c. Respondents’ Scientific Research Demonstrates a Benefit in Improving Blood Flow.............................................................. 97 3. Respondents’ Competent and Reliable Scientific Evidence Supports “Treat,” “Prevent,” and “Reduce the Risk of” Claims .............. 99 a. “Reduce the Risk” of Cardiovascular Disease............................ 100 b. “Prevent” Cardiovascular Disease .............................................. 101 c. “Treat” Cardiovascular Disease.................................................. 101 4. Competent and Reliable Scientific Evidence Supports Each of the Challenged Heart Advertisements .......................................................... 102 G. POM’s Erectile Claims Are True and Substantiated by Competent and Reliable Scientific Evidence............................................................................... 115 1. RCTs Are Not Required to Substantiate POM’s Erectile Claims ........... 116 2. Respondents Possess Competent
Load more

Recommended publications
  • Unrestricted Immigration and the Foreign Dominance Of
    Unrestricted Immigration and the Foreign Dominance of United States Nobel Prize Winners in Science: Irrefutable Data and Exemplary Family Narratives—Backup Data and Information Andrew A. Beveridge, Queens and Graduate Center CUNY and Social Explorer, Inc. Lynn Caporale, Strategic Scientific Advisor and Author The following slides were presented at the recent meeting of the American Association for the Advancement of Science. This project and paper is an outgrowth of that session, and will combine qualitative data on Nobel Prize Winners family histories along with analyses of the pattern of Nobel Winners. The first set of slides show some of the patterns so far found, and will be augmented for the formal paper. The second set of slides shows some examples of the Nobel families. The authors a developing a systematic data base of Nobel Winners (mainly US), their careers and their family histories. This turned out to be much more challenging than expected, since many winners do not emphasize their family origins in their own biographies or autobiographies or other commentary. Dr. Caporale has reached out to some laureates or their families to elicit that information. We plan to systematically compare the laureates to the population in the US at large, including immigrants and non‐immigrants at various periods. Outline of Presentation • A preliminary examination of the 609 Nobel Prize Winners, 291 of whom were at an American Institution when they received the Nobel in physics, chemistry or physiology and medicine • Will look at patterns of
    [Show full text]
  • The Federal Government: a Nobel Profession
    The Federal Government: A Nobel Profession A Report on Pathbreaking Nobel Laureates in Government 1901 - 2002 INTRODUCTION The Nobel Prize is synonymous with greatness. A list of Nobel Prize winners offers a quick register of the world’s best and brightest, whose accomplishments in literature, economics, medicine, science and peace have enriched the lives of millions. Over the past century, 270 Americans have received the Nobel Prize for innovation and ingenuity. Approximately one-fourth of these distinguished individuals are, or were, federal employees. Their Nobel contributions have resulted in the eradication of polio, the mapping of the human genome, the harnessing of atomic energy, the achievement of peace between nations, and advances in medicine that not only prolong our lives, but “This report should serve improve their quality. as an inspiration and a During Public Employees Recognition Week (May 4-10, 2003), in an effort to recognize and honor the reminder to us all of the ideas and accomplishments of federal workers past and present, the Partnership for Public Service offers innovation and nobility of this report highlighting 50 American Nobel laureates the work civil servants do whose award-winning achievements occurred while they served in government or whose public service every day and its far- work had an impact on their career achievements. They were honored for their contributions in the fields reaching impact.” of Physiology or Medicine, Economic Sciences, and Physics and Chemistry. Also included are five Americans whose work merited the Peace Prize. Despite this legacy of accomplishment, too few Americans see the federal government as an incubator for innovation and discovery.
    [Show full text]
  • Nobel Award Stirs up Debate on Nitric Oxide Breakthrough
    news Nobel award stirs up debate on nitric oxide breakthrough [LONDON] The Nobel committee has once again sparked controversy, particularly in Britain, with the award this week of the 1998 8 prize for physiology or medicine to pharma- cologists Robert Furchgott, of the State Uni- versity of New York, Louis Ignarro, of the University of California, Los Angeles, and Ferid Murad, of University of Texas Medical SULLIVAN NADEL/PAT AP/ADAM School in Houston. No-one is disputing that the pioneering work of the three US researchers on nitric oxide as a signalling molecule in the cardio- vascular system (see box) deserves the recog- nition of the committee. But many feel that a The winners: Robert Furchgott (left), Louis Ignarro and Ferid Murad. fourth name should also have been recog- nized — that of Salvador Moncada, currently pharmacology”. Moncada’s achievements edged. But he believes that the prize is thor- director of the Wolfson Institute for Biomed- were recognized when he was elected as a oughly deserved by Furchgott — without ical Research at University College London. foreign associate of the National Academy of whom “the field would not even exist” — The controversy originates in 1987, when Sciences in 1994. The citation says that he and says that he had nominated both Furch- a paper by Ignarro confirming the identity “discovered that mammalian vascular tis- gott and Ignarro for the prize. of endothelium-derived relaxing factor sues generate nitric oxide that is biosynthe- More outspoken support for Moncada (EDRF) and nitric oxide, as had been sized from L-arginine. He elucidated the rel- comes from Nobel laureate Cesar Milstein of hypothesized separately by him and Furch- evance of this pathway as a universal trans- the MRC Laborato- UCL gott, appeared in the Proceedings of the duction mechanism for the regulation of cell ry of Molecular National Academy of Sciences (84, function and communication”.
    [Show full text]
  • Close to the Edge: Co-Authorship Proximity of Nobel Laureates in Physiology Or Medicine, 1991 - 2010, to Cross-Disciplinary Brokers
    Close to the edge: Co-authorship proximity of Nobel laureates in Physiology or Medicine, 1991 - 2010, to cross-disciplinary brokers Chris Fields 528 Zinnia Court Sonoma, CA 95476 USA fi[email protected] January 2, 2015 Abstract Between 1991 and 2010, 45 scientists were honored with Nobel prizes in Physiology or Medicine. It is shown that these 45 Nobel laureates are separated, on average, by at most 2.8 co-authorship steps from at least one cross-disciplinary broker, defined as a researcher who has published co-authored papers both in some biomedical discipline and in some non-biomedical discipline. If Nobel laureates in Physiology or Medicine and their immediate collaborators can be regarded as forming the intuitive “center” of the biomedical sciences, then at least for this 20-year sample of Nobel laureates, the center of the biomedical sciences within the co-authorship graph of all of the sciences is closer to the edges of multiple non-biomedical disciplines than typical biomedical researchers are to each other. Keywords: Biomedicine; Co-authorship graphs; Cross-disciplinary brokerage; Graph cen- trality; Preferential attachment Running head: Proximity of Nobel laureates to cross-disciplinary brokers 1 1 Introduction It is intuitively tempting to visualize scientific disciplines as spheres, with highly produc- tive, well-funded intellectual and political leaders such as Nobel laureates occupying their centers and less productive, less well-funded researchers being increasingly peripheral. As preferential attachment mechanisms as well as the economics of employment tend to give the well-known and well-funded more collaborators than the less well-known and less well- funded (e.g.
    [Show full text]
  • Contributions of Civilizations to International Prizes
    CONTRIBUTIONS OF CIVILIZATIONS TO INTERNATIONAL PRIZES Split of Nobel prizes and Fields medals by civilization : PHYSICS .......................................................................................................................................................................... 1 CHEMISTRY .................................................................................................................................................................... 2 PHYSIOLOGY / MEDECINE .............................................................................................................................................. 3 LITERATURE ................................................................................................................................................................... 4 ECONOMY ...................................................................................................................................................................... 5 MATHEMATICS (Fields) .................................................................................................................................................. 5 PHYSICS Occidental / Judeo-christian (198) Alekseï Abrikossov / Zhores Alferov / Hannes Alfvén / Eric Allin Cornell / Luis Walter Alvarez / Carl David Anderson / Philip Warren Anderson / EdWard Victor Appleton / ArthUr Ashkin / John Bardeen / Barry C. Barish / Nikolay Basov / Henri BecqUerel / Johannes Georg Bednorz / Hans Bethe / Gerd Binnig / Patrick Blackett / Felix Bloch / Nicolaas Bloembergen
    [Show full text]
  • Commencement
    THE JOHNS HOPKINS UNIVERSITY Conferring of degrees COMMENCEMENT at the 2010 close of the 134th academic year May 21, 2010 8:40 a.m. Digitized by the Internet Archive in 2012 with funding from LYRASIS Members and Sloan Foundation http://archive.org/details/commencement2010 Contents Order of Seating ii Order of Procession 1 Order of Events 2 Commencement Speaker's Biography 6 Johns Hopkins Society of Scholars 7 Honorary Degree Citations 12 Academic Regalia 15 Awards 18 Honor Societies 28 Student Honors 32 Candidates for Degrees 38 Divisional Ceremonies Information 101 Please note that while //// degrees are conferred, only doctoral and bachelor's graduates process across the stage. Though taking photos from your seats during the ceremom is not prohibited, we request that guests respect each other's comfort and enjoyment by not standing and blocking other people's views. PhotOS of graduates can he purchased from Grad Images (www. grailunages.com) or (800) 424-3686. DVDs can he purchased from GradMemorj (www.gradmemory.com) or (866) 997-GRAD \\ i appreciate your cooperation! STAGE V I X ED EdD PY AD, DMA PY DMA, AD ED EdD NU DNP, PhD NU PhD, DNP BSPH DPH, PhD BSPH PhD, DPH SAIS PhD MEMO ME MD SAIS PhD ME PhD ME PhD EN PhD EN PhD AS PhD AS PhD CAREY Masters CAREY Masters EDUC CAGS, Masters EDUC CAGS, Masters PY Masters, Diplomas PY Masters, Diplomas Certificates Certificates NU Masters NU Masters BSPH Masters BSPH Masters SAIS Masters SAIS Masters ME Masters ME Masters EN Masters, Certificates EN Masters, Certificates < AS Masters, Certificates
    [Show full text]
  • Annual Report 2017
    67th Lindau Nobel Laureate Meeting 6th Lindau Meeting on Economic Sciences Annual Report 2017 The Lindau Nobel Laureate Meetings Contents »67 th Lindau Nobel Laureate Meeting (Chemistry) »6th Lindau Meeting on Economic Sciences Over the last 67 years, more than 450 Nobel Laureates have come 67th Lindau Nobel Laureate Meeting (Chemistry) Science as an Insurance Policy Against the Risks of Climate Change 10 The Interdependence of Research and Policymaking 82 to Lindau to meet the next generation of leading scientists. 25–30 June 2017 Keynote by Nobel Laureate Steven Chu Keynote by ECB President Mario Draghi The laureates shape the scientific programme with their topical #LiNo17 preferences. In various session types, they teach and discuss Opening Ceremony 14 Opening Ceremony 86 scientific and societal issues and provide invaluable feedback Scientific Chairpersons to the participating young scientists. – Astrid Gräslund, Professor of Biophysics, Department of New Friends Across Borders 16 An Inspiring Hothouse of Intergenerational 88 Biochemistry and Biophysics, Stockholm University, Sweden By Scientific Chairpersons Astrid Gräslund and Wolfgang Lubitz and Cross-Cultural Exchange Outstanding scientists and economists up to the age of 35 are – Wolfgang Lubitz, Director, Max Planck Institute By Scientific Chairpersons Torsten Persson and Klaus Schmidt invited to take part in the Lindau Meetings. The participants for Chemical Energy Conversion, Germany Nobel Laureates 18 include undergraduates, PhD students as well as post-doctoral Laureates 90 researchers. In order to participate in a meeting, they have to Nominating Institutions 22 pass a multi-step application and selection process. 6th Lindau Meeting on Economic Sciences Nominating Institutions 93 22–26 August 2017 Young Scientists 23 #LiNoEcon Young Economists 103 Scientific Chairpersons SCIENTIFIC PROGRAMME – Martin F.
    [Show full text]
  • Ferid Murad, at 80: a Legacy of Science, Medicine, and Mentorship
    Thomas Jefferson University Jefferson Digital Commons Department of Pharmacology and Experimental Department of Pharmacology and Experimental Therapeutics Faculty Papers Therapeutics 7-1-2016 Editorial: Ferid murad, at 80: A legacy of science, medicine, and mentorship Atta-Ur-Rahman The Kings College Follow this and additional works at: https://jdc.jefferson.edu/petfp Part of the Medicine and Health Sciences Commons Let us know how access to this document benefits ouy Recommended Citation Atta-Ur-Rahman, "Editorial: Ferid murad, at 80: A legacy of science, medicine, and mentorship" (2016). Department of Pharmacology and Experimental Therapeutics Faculty Papers. Paper 77. https://jdc.jefferson.edu/petfp/77 This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital Commons is a service of Thomas Jefferson University's Center for Teaching and Learning (CTL). The Commons is a showcase for Jefferson books and journals, peer-reviewed scholarly publications, unique historical collections from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and interested readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been accepted for inclusion in Department of Pharmacology and Experimental Therapeutics Faculty Papers by an authorized administrator of the Jefferson Digital Commons. For more information, please contact: [email protected]. Ferid Murad, MD, PhD at 80: A Legacy of Science, Medicine, and Mentorship Scott A. Waldman, MD, PhD, FCP, FAHA Department of Pharmacology and Experimental Therapeutics Sidney Kimmel Medical College Thomas Jefferson University 1020 Locust Street, 368 JAH Philadelphia, PA 19107 and Prof.
    [Show full text]
  • Lindau Nobel Laureate Meetings South African Alumni Narratives © Academy of Science of South Africa August 2020
    Lindau Nobel Laureate Meetings South African Alumni Narratives © Academy of Science of South Africa August 2020 ISBN 978-1-928496-28-1 Cite: Academy of Science of South Africa (ASSAf), (2020). DOI http://dx.doi.org/10.17159/assaf.2019/0063 Published by: Academy of Science of South Africa (ASSAf) PO Box 72135, Lynnwood Ridge, Pretoria, South Africa, 0040 Tel: +27 12 349 6600 • Fax: +27 86 576 9520 E-mail: [email protected] Reproduction is permitted, provided the source and publisher are appropriately acknowledged. The Academy of Science of South Africa (ASSAf) was inaugurated in May 1996. It was formed in response to the need for an Academy of Science consonant with the dawn of democracy in South Africa: activist in its mission of using science and scholarship for the benefit of society, with a mandate encompassing all scholarly disciplines that use an open-minded and evidence-based approach to build knowledge. ASSAf thus adopted in its name the term ‘science’ in the singular as reflecting a common way of enquiring rather than an aggregation of different disciplines. Its Members are elected on the basis of a combination of two principal criteria, academic excellence and significant contributions to society. The Parliament of South Africa passed the Academy of Science of South Africa Act (No 67 of 2001), which came into force on 15 May 2002. This made ASSAf the only academy of science in South Africa officially recognised by government and representing the country in the international community of science academies and elsewhere. Views expressed are those of the individuals and not necessarily those of the Academy nor a consensus view of the Academy based on an in-depth evidence-based study.
    [Show full text]
  • Nobelists Gone Wild Case Studies in the Domain Specificity of Critical Thinking Scott O
    chapter 2 Nobelists Gone Wild Case Studies in the Domain Specificity of Critical Thinking Scott O. Lilienfeld Emory University, University of Melbourne Candice Basterfield University of Melbourne Shauna M. Bowes Emory University Thomas H. Costello Emory University Introduction Research suggests that critical thinking skills are often surprisingly domain- specific. We survey the case histories of several Nobel Prize winners in the sciences to demonstrate that even extremely bright individuals can fall prey to bizarre ideas. These findings strongly suggest that intellectual brilliance and acceptance of weird ideas are not mutually incompatible. They also highlight the domain-specificity of critical thinking and the surprising independence of general intelligence from critical thinking. A number of cognitive errors, including bias blind spot and the senses of omniscience, omnipotence, and invulnerability; personality traits such as narcissism and excessive openness; and the “guru complex” may predispose highly intel- ligent individuals to disastrous critical thinking errors. Consider the following case examples: • Sir Isaac Newton (1642–1727) was among the most brilliant individuals who ever lived. Along with Leibnitz, he developed the mathematics of calculus. He formulated the basic principles of gravitation and three major laws of motion, which comprise the foundation for much of modern physics. At the same time, Newton invested much of his intel- lectual energy into alchemy, the mystical notion that one can transform 10 Downloaded from https://www.cambridge.org/core. University of California, Santa Cruz, on 21 Dec 2019 at 22:44:30, subject to the Cambridge Core terms of use, available at https://www.cambridge.org/core/terms. https://doi.org/10.1017/9781108684354.003 Nobelists Gone Wild 11 base metals into gold and silver (White, 1999).
    [Show full text]
  • Nobelists for Obama Letter
    An Open Letter to the American People September 25, 2008 This year's presidential election is among the most significant in our nation's history. The country urgently needs a visionary leader who can ensure the future of our traditional strengths in science and technology and who can harness those strengths to address many of our greatest problems: energy, disease, climate change, security, and economic competitiveness. We are convinced that Senator Barack Obama is such a leader, and we urge you to join us in supporting him. During the administration of George W. Bush, vital parts of our country's scientific enterprise have been damaged by stagnant or declining federal support. The government's scientific advisory process has been distorted by political considerations. As a result, our once dominant position in the scientific world has been shaken and our prosperity has been placed at risk. We have lost time critical for the development of new ways to provide energy, treat disease, reverse climate change, strengthen our security, and improve our economy. We have watched Senator Obama's approach to these issues with admiration. We especially applaud his emphasis during the campaign on the power of science and technology to enhance our nation's competitiveness. In particular, we support the measures he plans to take – through new initiatives in education and training, expanded research funding, an unbiased process for obtaining scientific advice, and an appropriate balance of basic and applied research – to meet the nation's and the world's most urgent needs. Senator Obama understands that Presidential leadership and federal investments in science and technology are crucial elements in successful governance of the world's leading country.
    [Show full text]
  • Munich) Has Activx Biosciences, and Was Previously Vice Announced That Paul President at Merck Research Laboratories
    PEOPLE Wilex (Munich) has ActivX Biosciences, and was previously vice announced that Paul president at Merck Research Laboratories. In Bevan, formerly research addition, Dr. Kozarich is a biotechnology director at Xenova professor at the Scripps Research Institute. Therapeutics and a member of Xenova Ortec International (New York) has Group’s executive board, announced the promotion of Ron Lipstein to has been appointed the company’s head of the position of CEO. Mr. Lipstein is a founder research and development and a member of of Ortec and has served as CFO since its the executive board. Dr. Bevan was most inception and as vice chairman for the past recently CEO of PharmAssociates, a pharma- two years. He will continue in his role as vice ceutical consulting firm that he founded in chairman. In addition, Costa Papastephanou, 1999. president of Ortec, will also assume the posi- tion of COO. Steven Katz, who has served as Stéphane Boissel has been appointed chief CEO since Ortec’s founding, will continue to financial officer at Innate Pharma (Marseille, serve as chairman of the board. France). Mr. Boissel has spent the past seven years with Groupe Lazard in France, Aton Pharma (Tarrytown, NY) has Singapore, and Hong Kong, and was most announced the appointment of Carolyn M. recently director of investments at Eurazeo, a Paradise as senior vice president and chief member of the Lazard group. medical officer. Dr. Paradise previously served as executive vice president, clinical Joseph R. Chinnici has been elected to the operations and regulatory affairs and chief board of directors at Guilford medical officer at Cell Therapeutics.
    [Show full text]